SCHEMBL4682941

SCHEMBL4682941

COC(=O)c1cncc(-n2cc(C3=C(c4ccccc4OC)C(=O)NC3=O)c3cc(Cl)ccc32)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 14/20 0.43
QPCT Q16769 5/20 0.43
GSK3A P49840 4/20 0.43
STK10 O94804 2/20 0.43
SLK Q9H2G2 2/20 0.43
CLK2 P49760 1/20 0.43
STK33 Q9BYT3 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
TLK1 Q9UKI8 1/20 0.43
PRKCA P17252 3/20 0.43
ALPL P05186 1/20 0.41
MEN1 O00255 1/20 0.39
RGS12 O14924 1/20 0.39
GMNN O75496 1/20 0.39
USP2 O75604 1/20 0.39
CCNB2 O95067 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4682934 0.92 GSK3B (0.44) GSK3BQPCTGSK3ASTK10SLK
SCHEMBL4679888 0.92 GSK3B (0.44) GSK3BQPCTGSK3ASTK10SLK
SCHEMBL1127773 0.82 GSK3B (0.51) GSK3BPRKCA
SCHEMBL2955240 0.76 GSK3B (0.57) GSK3BQPCTPRKCACDK4CCND1
SCHEMBL1127716 0.75 GSK3B (0.64) GSK3BQPCTPRKCACDK4CCNA2
SCHEMBL14488857 0.73 KCNH2 (0.44) ALPLCYP1A2POLBCYP2C19KMT2A
SCHEMBL14499020 0.68 GSK3B (0.38) GSK3BQPCTGSK3ASTK10SLK
SCHEMBL14489217 0.68 CYP11B1 (0.50) ALPL
SCHEMBL14555040 0.66 CCNE2 (0.66) GSK3BGSK3APRKCACDK4CCND1
SCHEMBL1127953 0.65 GSK3B (0.68) GSK3BPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513520-B1 SUBSTITUTED PYRROLINES AS KINASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2008-09-24 EP disclosed
US-7232906-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BG) 2007-06-19 US disclosed
US-7232906-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BG) 2007-06-19 US disclosed
US-7232906-B2 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BG) 2007-06-19 US disclosed
US-20040054180-A1 Substituted pyrrolines as kinase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2004-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040054180-A1 Substituted pyrrolines as kinase inhibitors PRKDC, MAP2K2, TTK GSK3B 880/4885QPCT 2577/4885GSK3A 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.